S95031
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $85,258 | 6 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $85,258 | 6 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Phase 3, multicenter, double-blind, randomized, placebo-controlled study of ivosidenib in participants ?18 years of age with locally advanced or metastatic conventional chondrosarcoma with an IDH1 mutation, untreated or previously treated with 1 systemic treatment regimen (CHONQUER study) | Servier BioInnovation | $85,258 | 0 |
Top Doctors Receiving Payments for S95031
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Omaha, NE | $85,258 | 6 |
Manufacturing Companies
- Servier BioInnovation $85,258
Product Information
- Type Drug
- Total Payments $85,258
- Total Doctors 0
- Transactions 6
About S95031
S95031 is a drug associated with $85,258 in payments to 0 healthcare providers, recorded across 6 transactions in the CMS Open Payments database. The primary manufacturer is Servier BioInnovation.
Payment data is available from 2024 to 2024. In 2024, $85,258 was paid across 6 transactions to 0 doctors.
The most common payment nature for S95031 is "Unspecified" ($85,258, 100.0% of total).
S95031 is associated with 1 research study, including "Phase 3, multicenter, double-blind, randomized, placebo-controlled study of ivosidenib in participants ?18 years of age with locally advanced or metastatic conventional chondrosarcoma with an IDH1 mutation, untreated or previously treated with 1 systemic treatment regimen (CHONQUER study)" ($85,258).